James A. Schoeneck is a seasoned biotechnology executive serving as Chairman of the Board and Director of Calidi Biotherapeutics, Inc. (CLDI) since July 2020, with his role as Chairman beginning in April 2025.( He is also a Director at FibroGen, Inc. since April 2010, where he acted as Interim CEO from 2019 to 2020, and previously served as CEO of Depomed, Inc. from 2011 to 2017, transforming it into a commercial specialty pharmaceutical company.(

Schoeneck's career highlights include CEO roles at BrainCells Inc. (2005-2011), ActivX BioSciences, and Prometheus Laboratories Inc., as well as Vice President and General Manager of Immunology at Centocor, Inc., where he oversaw the launch of Remicade®.( Earlier, he held increasing sales and marketing responsibilities at Rhone-Poulenc Rorer, Inc. (now Sanofi) for 13 years. He holds a BS in Education from Jacksonville State University.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.